Scarica l'app Stockscreener
13.45
4.54%
-0.64
Dopo l'orario di chiusura:
13.50
0.05
+0.37%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$14.09
Aprire:
$14.515
Volume 24 ore:
4.94M
Relative Volume:
1.13
Capitalizzazione di mercato:
$953.61M
Reddito:
-
Utile/perdita netta:
$-117.81M
Rapporto P/E:
-7.1543
EPS:
-1.88
Flusso di cassa netto:
$74.30M
1 W Prestazione:
-21.69%
1M Prestazione:
+17.98%
6M Prestazione:
+329.71%
1 anno Prestazione:
+36.00%
Intervallo 1D:
$13.41
$16.14
Intervallo di 1 settimana:
$13.41
$17.63
Portata 52W:
$2.95
$17.65
Omeros Corporation Stock (OMER) Company Profile
Nome
Omeros Corporation
Settore
Industria
Telefono
206-676-5000
Indirizzo
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Confronta OMER con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
13.45 | 998.99M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-23 | Iniziato | D. Boral Capital | Buy |
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
| 2022-12-08 | Downgrade | UBS | Buy → Neutral |
| 2022-11-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-06-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-10-01 | Downgrade | Maxim Group | Buy → Hold |
| 2021-10-01 | Downgrade | Wedbush | Neutral → Underperform |
| 2021-09-27 | Iniziato | JP Morgan | Neutral |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-08-21 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-14 | Reiterato | Maxim Group | Buy |
| 2019-05-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-12 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-23 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-03-05 | Downgrade | Needham | Buy → Hold |
| 2017-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2017-05-11 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | Reiterato | Maxim Group | Buy |
| 2017-03-17 | Reiterato | Needham | Buy |
| 2016-11-16 | Reiterato | Wedbush | Outperform |
| 2016-11-10 | Reiterato | Needham | Buy |
| 2016-08-10 | Reiterato | Maxim Group | Buy |
| 2016-06-03 | Iniziato | Cantor Fitzgerald | Buy |
| 2016-03-02 | Reiterato | Needham | Buy |
| 2016-02-29 | Reiterato | Wedbush | Outperform |
| 2015-11-11 | Reiterato | Needham | Buy |
| 2015-08-18 | Reiterato | WBB Securities | Strong Buy |
| 2015-08-10 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Omeros Corporation Borsa (OMER) Ultime notizie
Why Omeros Corporation stock could benefit from AI revolution2025 Bull vs Bear & Free Low Drawdown Momentum Trade Ideas - ulpravda.ru
Why retail investors pile into Omeros Corporation stock2025 Sector Review & Technical Entry and Exit Tips - ulpravda.ru
Omeros (NASDAQ:OMER) Trading Up 10.3% on Analyst Upgrade - MarketBeat
Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set - TechStock²
OMER: HC Wainwright & Co. Raises Price Target to $40 with Buy Ra - GuruFocus
OMER's Rating Maintained as 'Buy' with $36 Price Target by Analyst | OMER Stock News - GuruFocus
Balanced Risk/Reward and Gradual Yartemlea Ramp Justify Hold Rating on Omeros - TipRanks
Omeros (NASDAQ:OMER) Price Target Raised to $40.00 - MarketBeat
Omeros (NASDAQ:OMER) Earns Buy Rating from D. Boral Capital - MarketBeat
Omeros Stock Enters Commercial Phase with Key Drug Launch - AD HOC NEWS
Omeros prices transplant complication drug at $36,000 per dose - whbl.com
Why did Omeros stock jump 5% in after-hours trading today? - MSN
Why Did Omeros Stock Jump 5% In After-Hours Trading Today? - Stocktwits
Omeros Details Yarcomlia U.S. Launch After FDA Approval, Pricing and Supply Outlook in Focus - MarketBeat
Is Omeros Corporation stock attractive for income investorsGrowth Stock Opportunities & Affordable Investment Portfolio - ulpravda.ru
Can Omeros Corporation stock deliver surprise earnings beatDay Trading Setups & Outstanding Growth Portfolio - ulpravda.ru
Omeros Corporation (OMER): Novo Nordisk deal creating buzz - MSN
Omeros (NASDAQ:OMER) Trading Down 6%Should You Sell? - MarketBeat
Assessing Omeros (OMER) Valuation After YARTEMLEA’s FDA Approval And Planned US Launch - simplywall.st
Will FDA Approval of YARTEMLEA in TA-TMA Redefine Omeros' (OMER) Commercial Trajectory? - simplywall.st
Omeros (NASDAQ:OMER) Sets New 12-Month HighStill a Buy? - MarketBeat
Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Omeros stock jumps premarket after FDA approves first drug for rare transplant complication — retail sees big upside - MSN
Will Omeros Corporation stock deliver better than expected guidanceGrowth Stock Opportunities & Ride the Wave of Market-Beating Growth - bollywoodhelpline.com
Omeros (NASDAQ:OMER) Trading Up 4.6%Here's Why - MarketBeat
Best Pharmaceutical Stocks To Watch TodayDecember 24th - MarketBeat
Retail’s Christmas Eve watchlist: Omeros, Nike, Citi, Dynavax and Agios spark most market chatter - MSN
Commit To Buy Omeros At $10, Earn 26.6% Annualized Using Options - Nasdaq
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA - Yahoo Finance
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder - MSN
Omeros Corp Announces FDA Approval of YARTEMLEA for TA-TMA - TradingView — Track All Markets
Omeros (NASDAQ: OMER) secures FDA nod for YARTEMLEA in TA-TMA - Stock Titan
Omeros: Why The Novo Nordisk Deal Is More Important Than FDA Approval (Rating Upgrade) - Seeking Alpha
FDA Clears First Therapy for Transplant Associated Thrombotic Microangiopathy - prismedia.ai
Omeros to resume trading at 9:50 AM ET - MSN
D Boral Capital notes Omeros’ YARTEMLEA FDA win, maintains buy rating - MSN
Why Omeros stock skyrocketed today - MSN
Omeros Announces New Date for YARTEMLEA® Approval Conference Call - Caledonian Record
Omeros stock garners high retail attention ahead of FDA verdict for life-saving drug - MSN
Omeros scores its 1st FDA nod as stem cell transplant drug Yartemlea approved - Fierce Pharma
Omeros (NASDAQ:OMER) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Biohaven, Omeros And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Omeros rockets as FDA approves Yartemlea - The Pharma Letter
Analysts Are Neutral on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Omeros (OMER) - The Globe and Mail
WBB Securities Reaffirms Their Buy Rating on Omeros (OMER) - The Globe and Mail
Omeros (OMER): Revisiting Valuation After a Powerful Multi‑Year Share Price Repricing - Yahoo Finance
Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook - TechStock²
Omeros wins FDA nod for transplant therapy - MSN
Omeros (NASDAQ:OMER) Hits New 12-Month HighTime to Buy? - MarketBeat
Omeros (OMER) Valuation After FDA Approval of First TA-TMA Therapy Yartemlea and Shift to Commercial Stage - simplywall.st
Corient Private Wealth LLC Reduces Stock Holdings in Omeros Corporation $OMER - MarketBeat
Omeros Corporation Azioni (OMER) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):